vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and OLAPLEX HOLDINGS, INC. (OLPX). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $105.1M, roughly 1.9× OLAPLEX HOLDINGS, INC.). OLAPLEX HOLDINGS, INC. runs the higher net margin — -12.5% vs -14.6%, a 2.1% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 4.3%). OLAPLEX HOLDINGS, INC. produced more free cash flow last quarter ($32.6M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 3.1%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Olaplex Holdings, Inc. is a specialty beauty company developing and selling patented bond-repair hair care products. It runs three core segments: professional salon distribution, direct-to-consumer sales, and third-party retail, serving customers across North America, Europe, and Asia-Pacific with products that repair and protect damaged hair.
AXSM vs OLPX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $105.1M |
| Net Profit | $-28.6M | $-13.1M |
| Gross Margin | — | 68.0% |
| Operating Margin | -13.8% | -4.3% |
| Net Margin | -14.6% | -12.5% |
| Revenue YoY | 65.0% | 4.3% |
| Net Profit YoY | 61.9% | -48.9% |
| EPS (diluted) | $-0.55 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $105.1M | ||
| Q3 25 | $171.0M | $114.6M | ||
| Q2 25 | $150.0M | $106.3M | ||
| Q1 25 | $121.5M | $97.0M | ||
| Q4 24 | $118.8M | $100.7M | ||
| Q3 24 | $104.8M | $119.1M | ||
| Q2 24 | $87.2M | $103.9M | ||
| Q1 24 | $75.0M | $98.9M |
| Q4 25 | $-28.6M | $-13.1M | ||
| Q3 25 | $-47.2M | $11.1M | ||
| Q2 25 | $-48.0M | $-7.7M | ||
| Q1 25 | $-59.4M | $465.0K | ||
| Q4 24 | $-74.9M | $-8.8M | ||
| Q3 24 | $-64.6M | $14.8M | ||
| Q2 24 | $-79.3M | $5.8M | ||
| Q1 24 | $-68.4M | $7.7M |
| Q4 25 | — | 68.0% | ||
| Q3 25 | — | 69.1% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.3% | ||
| Q3 24 | — | 68.6% | ||
| Q2 24 | — | 69.7% | ||
| Q1 24 | — | 72.1% |
| Q4 25 | -13.8% | -4.3% | ||
| Q3 25 | -27.0% | 3.7% | ||
| Q2 25 | -24.5% | -1.1% | ||
| Q1 25 | -46.9% | 8.7% | ||
| Q4 24 | -61.1% | 3.0% | ||
| Q3 24 | -59.8% | 23.5% | ||
| Q2 24 | -89.5% | 15.7% | ||
| Q1 24 | -89.7% | 19.8% |
| Q4 25 | -14.6% | -12.5% | ||
| Q3 25 | -27.6% | 9.7% | ||
| Q2 25 | -32.0% | -7.3% | ||
| Q1 25 | -48.9% | 0.5% | ||
| Q4 24 | -63.1% | -8.7% | ||
| Q3 24 | -61.7% | 12.4% | ||
| Q2 24 | -91.0% | 5.6% | ||
| Q1 24 | -91.1% | 7.8% |
| Q4 25 | $-0.55 | $-0.02 | ||
| Q3 25 | $-0.94 | $0.02 | ||
| Q2 25 | $-0.97 | $-0.01 | ||
| Q1 25 | $-1.22 | $0.00 | ||
| Q4 24 | $-1.54 | $-0.01 | ||
| Q3 24 | $-1.34 | $0.02 | ||
| Q2 24 | $-1.67 | $0.01 | ||
| Q1 24 | $-1.44 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $318.7M |
| Total DebtLower is stronger | — | $352.3M |
| Stockholders' EquityBook value | $88.3M | $879.4M |
| Total Assets | $689.8M | $1.5B |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $318.7M | ||
| Q3 25 | $325.3M | $286.4M | ||
| Q2 25 | $303.0M | $289.3M | ||
| Q1 25 | $300.9M | $580.9M | ||
| Q4 24 | $315.4M | $586.0M | ||
| Q3 24 | $327.3M | $538.8M | ||
| Q2 24 | $315.7M | $507.9M | ||
| Q1 24 | $331.4M | $507.5M |
| Q4 25 | — | $352.3M | ||
| Q3 25 | — | $352.1M | ||
| Q2 25 | — | $351.9M | ||
| Q1 25 | — | $649.1M | ||
| Q4 24 | — | $650.5M | ||
| Q3 24 | — | $651.8M | ||
| Q2 24 | — | $653.1M | ||
| Q1 24 | — | $654.4M |
| Q4 25 | $88.3M | $879.4M | ||
| Q3 25 | $73.7M | $888.7M | ||
| Q2 25 | $73.1M | $874.2M | ||
| Q1 25 | $53.2M | $878.3M | ||
| Q4 24 | $57.0M | $874.4M | ||
| Q3 24 | $92.9M | $879.7M | ||
| Q2 24 | $102.9M | $863.3M | ||
| Q1 24 | $144.0M | $855.7M |
| Q4 25 | $689.8M | $1.5B | ||
| Q3 25 | $669.3M | $1.5B | ||
| Q2 25 | $639.8M | $1.5B | ||
| Q1 25 | $596.7M | $1.8B | ||
| Q4 24 | $568.5M | $1.8B | ||
| Q3 24 | $561.5M | $1.8B | ||
| Q2 24 | $548.2M | $1.8B | ||
| Q1 24 | $545.7M | $1.8B |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.40× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.76× | ||
| Q1 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $32.7M |
| Free Cash FlowOCF − Capex | $-18.7M | $32.6M |
| FCF MarginFCF / Revenue | -9.6% | 31.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $58.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $32.7M | ||
| Q3 25 | $1.0M | $8.0M | ||
| Q2 25 | $-32.4M | $20.9M | ||
| Q1 25 | $-43.4M | $-2.9M | ||
| Q4 24 | $-26.2M | $49.7M | ||
| Q3 24 | $-18.6M | $33.5M | ||
| Q2 24 | $-30.1M | $16.2M | ||
| Q1 24 | $-53.5M | $43.7M |
| Q4 25 | $-18.7M | $32.6M | ||
| Q3 25 | $988.0K | $7.9M | ||
| Q2 25 | $-32.4M | $20.8M | ||
| Q1 25 | $-43.7M | $-3.0M | ||
| Q4 24 | $-26.2M | $49.2M | ||
| Q3 24 | $-18.7M | $33.3M | ||
| Q2 24 | $-30.2M | $16.1M | ||
| Q1 24 | $-53.6M | $43.3M |
| Q4 25 | -9.6% | 31.0% | ||
| Q3 25 | 0.6% | 6.9% | ||
| Q2 25 | -21.6% | 19.6% | ||
| Q1 25 | -36.0% | -3.1% | ||
| Q4 24 | -22.1% | 48.9% | ||
| Q3 24 | -17.9% | 28.0% | ||
| Q2 24 | -34.6% | 15.5% | ||
| Q1 24 | -71.4% | 43.7% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.3% | 0.0% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.1% | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -6.27× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.26× | ||
| Q2 24 | — | 2.81× | ||
| Q1 24 | — | 5.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
OLPX
| Sales Channel Directly To Consumer | $43.6M | 42% |
| Sales Channel Through Intermediary Professional | $36.8M | 35% |
| Sales Channel Through Intermediary Specialty Retail | $24.7M | 23% |
